Abbott and Reata Pharmaceuticals Announce Agreement
- Details
- Category: Abbott
Abbott and Reata Pharmaceuticals have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Pfizer Elects CEO Ian Read as Chairman of the Board
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that its Board of Directors has elected current President and Chief Executive Officer, Ian Read, as Chairman of the Board and Chief Executive Officer, effective immediately.
Most couples prefer spontaneity in the bedroom
- Details
- Category: Eli Lilly and Company
Sex is spontaneous, or unplanned, for the majority of men and women in the U.S. and around the world, a recent survey found. In the U.S., 76 percent of all respondents said they do not plan ahead for sex, compared to the global average of 86 percent.
Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
- Details
- Category: Novartis
Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival)[1].
AstraZeneca to acquire generics company to broaden patient access to medicines in China
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement to acquire Guangdong BeiKang Pharmaceutical Company Ltd, a privately-owned generics manufacturing company, based in Conghua City, Guangdong province, China.
AstraZeneca to streamline US sales organisation
- Details
- Category: AstraZeneca
AstraZeneca announced that it will reduce its US sales force by approximately 1,150 leadership positions and sales representatives as part of the company's ongoing strategy to operate its business more efficiently to best serve patients in the US.
Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.
More Pharma News ...
- Pfizer Completes Acquisition of Excaliard
- Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals
- Novartis Foundation symposium looks at impact of Information and Communication Technology
- Understand Barriers to Progression of Insulin Treatment
- Ranbaxy announces launch of Atorvastatin, generic Lipitor®, in the U.S.
- Sanofi Confirms its Decades-Long Commitment to the Fight against Malaria
- AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures